semaglutide news november 2025 supply The Food and Drug Administration's crackdown on cheaper, independently produced versions GLP-1 Pipeline Update: November 2025
Description
| 41 comments on LinkedIn
Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans
Xigduo XR is an effective treatment for Type 2 Diabetes
Antibodies and small molecules that interact with incretin targets are also being developed, as well as agents to modulate mitochondrial function, fatty acid receptors and receptors for selected gastrointestinal and adipocyte peptides that affect appetite or pathways of nutrient metabolism
That rule is a heuristic, not a biological law
